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Background
In this module, you will learn about targeted testing and the diagnosis of latent tuberculosis infection 
(LTBI) and tuberculosis (TB) disease. Targeted testing is a TB control strategy that is used to identify 
people who have LTBI, are at high risk for developing TB disease, and would benefit from treatment. LTBI 
is diagnosed with an interferon-gamma release assay (IGRA) or the Mantoux tuberculin skin test (TST).
It is important to medically evaluate people who have symptoms of TB disease; if they are found to have 
TB disease, they need treatment to be cured and to help stop the transmission of TB to others. For this 
reason, the diagnosis of TB disease is crucial to controlling the spread of TB in homes and communities. 
In most cases, TB disease is diagnosed with certain laboratory tests. For patients who may have 
pulmonary TB disease, a chest x-ray is also useful for diagnosis.
Note: The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in  
a self-study format. The target audiences include outreach workers, nurses, physicians, administrators, health educators, and 
students from a variety of settings. The Modules should not be used as a substitute for guidelines and should not be used for 
patient care decisions. 
Objectives define
explain
list
describe
After working through this module, you will be able to
1. Identify high-risk groups for targeted testing.
2. Describe how to interpret an interferon-gamma release assay.
3. Describe how to place, read, and interpret a Mantoux tuberculin skin test.
4. Discuss considerations for using either an interferon-gamma release assay 
or the Mantoux tuberculin skin test for diagnosing latent TB infection.
5. Describe the components of a medical evaluation for  
diagnosing TB disease.
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Doctor reviewing a chest x-ray.
New Terms
New terms introduced in this module are included below. These terms appear in bold in the module text.
acid-fast bacilli (AFB)—mycobacteria that when stained, 
retain color even after they have been washed in an 
acid solution; may be detected under a microscope in a 
stained smear
anergy—the inability to react to a skin test because of a 
weakened immune system, often caused by HIV infection 
or severe illness
antigen—protein substances that can produce an 
immune response (such as CFP-10, ESAT-6, or those  
in PPD)
bacteriologic examination—tests done in a 
mycobacteriology laboratory to aid diagnosis of TB 
disease; includes examining a specimen under a 
microscope, culturing the specimen, and testing for  
drug susceptibility
baseline skin test—a tuberculin skin test (TST) given to 
employees or residents in certain facilities when they start 
their job or enter the facility (see TB testing program and 
two-step testing)
BCG—bacille Calmette-Guérin (BCG), a vaccine for TB 
disease that is used in many countries but rarely used in 
the United States; may cause a false-positive reaction to 
the TST but does not affect interferon-gamma release 
assay (IGRA) results
boosted reaction—a positive reaction to a TST, due to a 
boosted immune response from a skin test given up to 
a year earlier; occurs in people who were infected a long 
time ago and whose ability to react to tuberculin has 
lessened. Two-step testing is used in TB testing programs 
to tell the difference between boosted reactions and 
reactions caused by recent infection (see booster 
phenomenon and two-step testing).
booster phenomenon—a phenomenon in which people 
(especially older adults) who are skin tested many years 
after becoming infected with M. tuberculosis may have a 
negative reaction to an initial TST, followed by a positive 
reaction to a TST given up to a year later; this happens 
because the first TST boosts the immune response. 
Two-step testing is used in TB testing programs to tell 
the difference between boosted reactions and reactions 
caused by recent infection (see two-step testing).
bronchoscopy—a procedure used to obtain pulmonary 
secretions or lung tissue with an instrument called a 
bronchoscope; used only when patients cannot cough  
up sputum on their own and an induced specimen 
cannot be obtained
cavity—a hollow space within the lung, visible on a chest 
x-ray, that may contain many tubercle bacilli; often occurs 
in people with severe pulmonary TB disease
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CFP-10—one of the antigens used in IGRAs that is found 
in M. tuberculosis strains but not in BCG vaccine strains
clinician—a physician, physician’s assistant, or nurse
colonies—groups of mycobacteria that have grown on 
solid media 
control—a standard of comparison for checking or 
verifying the results of an experiment
culture—to grow organisms in media (substances 
containing nutrients) so that they or the product of this 
process can be identified; a positive culture for  
M. tuberculosis contains tubercle bacilli, whereas a 
negative culture contains no detectable tubercle bacilli
drug-resistant—an organism’s ability to grow despite the 
presence of a particular drug
drug susceptibility pattern—the list of antituberculosis 
drugs to which a strain of tubercle bacilli is susceptible 
and to which it is resistant
erythema—redness around the site of the injection when 
a TST is done; erythema is not measured as part of the 
reaction size because redness does not indicate that a 
person has TB infection
ESAT-6—one of the antigens used in IGRAs that is found 
in M. tuberculosis strains but not in BCG vaccine strains
exposure to TB—time spent with or near someone who 
has infectious TB disease 
false-negative reaction—a negative reaction to the TST or 
IGRA in a person who has TB infection
false-positive reaction—a positive reaction to the TST or 
IGRA in a person who does not have TB infection
gastric washing—a procedure done by inserting a 
tube through the patient’s nose and passing it into the 
stomach; may be useful for obtaining a specimen for 
culture from children, who produce little or no sputum 
when they cough
GeneXpert—a semi-automated molecular diagnostic 
system. See Xpert MTB/RIF assay.
genotype—distinct genetic pattern of an organism
genotyping—a laboratory-based method that can 
determine the genetic pattern of the strain of  
M. tuberculosis that caused TB disease in a person
induced sputum—sputum that is obtained by having the 
patient inhale a saline (salt water) mist, causing the patient 
to cough deeply; this procedure is used to help patients 
cough up sputum if they cannot do so on their own
induration—swelling that can be felt around the site 
of injection after a TST is done; the reaction size is the 
diameter of the swollen area, measured across the forearm
infiltrate—a collection of fluid and cells in the tissues of 
the lung; visible on a chest x-ray in people with pulmonary 
TB disease
interferon-gamma (IFN-γ)—protein that is normally 
produced by the body in response to infection. IGRA 
interpretations are based on the amount of IFN-γ that is 
released or on the number of cells that release IFN-γ.
interferon-gamma release assay (IGRA)—a type of blood 
test that measures a person’s immune reactivity to  
M. tuberculosis. In the United States, the QuantiFERON®-TB 
Gold Plus (QFT-Plus) and the T-SPOT®.TB test (T-Spot) are 
currently available IGRAs.
isolate—a group of organisms isolated or separated  
from a specimen; in an M. tuberculosis isolate, the 
organisms have been grown in culture and identified as 
M. tuberculosis
malaise—a feeling of general discomfort or illness
Mantoux tuberculin skin test (TST)—a method of testing 
for TB infection; a needle and syringe are used to inject 
0.1 ml (5 tuberculin units) of purified protein derivative 
(PPD) tuberculin solution between the layers of the skin 
(intradermally), usually on the forearm; the reaction to this 
test, usually a small swollen area (induration), is measured 
48 to 72 hours after the injection and is interpreted 
as positive or negative depending on the size of the 
reaction and the patient’s risk factors for TB; the routine 
methodology for tuberculin skin testing worldwide; 
supersedes all older methods
media—substances containing special nutrients and used 
for growing cultures of bacteria found in specimens
medical history—the part of a patient’s life history that 
is important for diagnosing and treating TB infection or 
disease, including history of exposure, symptoms, previous 
diagnosis of TB infection or disease, and risk factors for  
TB disease
Module 3 – Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease4
TB testing program—a program in which 
employees and residents of a facility are periodically 
tested for TB; done to identify people who have TB 
infection and possibly TB disease and to determine 
whether TB is being transmitted in the facility
T-SPOT®.TB Test (T-Spot)—an interferon-gamma 
release assay (blood test) used to determine TB 
infection; the T-Spot measures the number of   
T cells that secrete IFN-γ upon  activation  by  
M. tuberculosis antigens
tuberculin—a substance made from tubercle bacilli 
that have been killed by heating; used to determine 
whether a person has TB infection. Tuberculin is not 
a vaccine.
tuberculin skin test (TST)—a test used to detect TB 
infection (see Mantoux tuberculin skin test)
tuberculin unit—a standard strength of tuberculin 
used in the United States and Canada; a strength of 5 
tuberculin units is used for the Mantoux TST with PPD
two-step testing—a strategy used in TB testing 
programs to distinguish a boosted reaction (caused 
by TB infection that occurred many years ago) from 
a reaction caused by recent infection. If a person has 
a negative reaction to an initial skin test, a second 
test is given 1 to 3 weeks later; a positive reaction 
to the second test probably represents a boosted 
reaction, not recent infection. Two-step testing is 
used in many TB testing programs for skin testing 
employees when they start their job.
window period—the time between a person’s last 
exposure to infectious TB and when a TST or IGRA 
can reliably detect infection with M. tuberculosis 
Xpert MTB/RIF assay—a nucleic acid amplification 
(NAA) test that simultaneously identifies 
Mycobacterium tuberculosis complex and rifampin 
resistance in a sputum sample
mycobacteriology laboratory—a laboratory that deals 
specifically with M. tuberculosis and other mycobacteria
nucleic acid amplification (NAA)—a technique that 
amplifies (copies) DNA and RNA segments. Often used 
in assays to directly detect microorganisms in sputum 
specimens.
polymerase chain reaction (PCR)—a type of NAA used to 
make many copies of a segment of DNA or RNA
PPD (purified protein derivative)—the type of tuberculin 
used in the Mantoux tuberculin skin test
QuantiFERON®-TB Gold Plus (QFT-Plus)—an interferon-
gamma release assay (blood test) used to determine TB 
infection. The QFT-Plus measures the response of immune 
cells to simulated TB proteins when they are mixed with a 
small amount of whole blood.
skin test conversion—a change in a skin test reaction from 
negative to positive between testing intervals
smear—a specimen that has been smeared onto a glass 
slide, stained, washed in an acid solution, and then placed 
under the microscope for examination; used to detect 
acid-fast bacilli in a specimen
sputum—phlegm from deep in the lungs, coughed 
up and collected in a sterile container for processing 
and examination
susceptible—an organism’s ability to be killed by a 
particular drug
symptoms of TB disease—noticeable conditions caused 
by TB disease. The symptoms of pulmonary TB disease 
include coughing, pain in the chest when breathing or 
coughing, and coughing up sputum or blood. The  
general symptoms of TB disease (pulmonary or 
extrapulmonary) include weight loss, fatigue, malaise, 
fever, and drenching night sweats. The symptoms of 
extrapulmonary TB disease depend on the part of the 
body that is affected by the disease.
targeted testing—a TB control strategy to identify persons 
with latent TB infection who are at high risk for developing 
TB disease and who would benefit from treatment
New Terms (continued)
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Targeted Testing
Targeted testing is the TB control strategy that is used to identify and treat persons with latent TB 
infection (LTBI) who are at high risk for developing TB disease. Identifying persons with LTBI is important 
to the goal of TB elimination because LTBI treatment can prevent these persons from developing TB 
disease and thereby stop the further spread of TB to others.
Targeted testing is the TB control strategy that is used to identify and  
treat persons with latent TB infection (LTBI) who are at high risk for  
developing TB disease once infected with M. tuberculosis.
Thus, during routine patient evaluations, health care providers should identify persons who are at high 
risk for TB and test them for LTBI. However, TB testing activities should be done only when there is a 
plan for follow-up care to evaluate and treat all individuals diagnosed with LTBI or TB disease. Healthcare 
agencies or other facilities should consult with the local health department before starting a TB testing 
program to make sure that any person whose test result is positive will have access to follow-up care. 
People who are not at high risk for LTBI generally should not be tested. Testing in low-risk populations 
can take resources away from other important activities. Also, positive test results in low-risk populations 
are sometimes inaccurate. However, there may be instances in which health care providers are asked 
to test individuals who are not generally considered as high risk (for example, daycare center workers, 
teachers, and college students) because of local policies and procedures.
People who are not at high risk for LTBI generally should not be tested.
Identifying High-Risk Groups for TB Testing
High-risk groups can be divided into two categories: 
zz People who are at high risk for exposure to or infection with M. tuberculosis 
zz People who are at high risk for developing TB disease once infected with M. tuberculosis
Flexibility should be used in defining high-risk groups for testing. Since the epidemiology of TB can 
change, the risk of LTBI or TB disease among groups may change over time. Groups that are currently 
identified as being at low-risk may later be considered high priority. Moreover, because of the 
differences in populations from one community to another, definitions of high risk should be made at 
the local (city, county, or state) level according to local demographics and TB epidemiology.
Flexibility should be used in defining high-risk groups for testing.
In general, however, high-risk groups listed in both categories of Table 3.1 should be tested.
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Table 3.1 –  Groups at High Risk for TB Infection and TB Disease.
People at High Risk for Exposure  
to or Infection with M. tuberculosis
People at High Risk for Developing TB  
Disease after Infection with M. tuberculosis
• Contacts of people known or suspected to  
have TB disease
• People born in or who frequently travel 
to countries where TB disease is common, 
including Mexico, the Philippines, Vietnam,  
India, China, Haiti, and Guatemala, or other 
countries with high rates of TB 
• People who live in, or have lived in, high-risk 
congregate settings (for example, homeless 
shelters or correctional facilities)
• Employees of high-risk congregate settings
• Health care workers who serve patients  
with TB disease
• Populations defined locally as having an 
increased incidence of LTBI or TB disease, 
possibly including medically underserved,  
low-income populations, or persons who  
abuse drugs or alcohol
• Infants, children, and adolescents exposed 
to adults who are at increased risk for  
LTBI or TB disease
• People living with HIV
• Children younger than 5 years of age
• People recently infected with M. tuberculosis 
(within the past 2 years)
• People with a history of untreated or 
inadequately treated TB disease
• Persons who are receiving immunosuppressive 
therapy such as tumor necrosis factor-alpha 
(TNF) antagonists, systemic corticosteroids 
equivalent to/greater than 15 mg of prednisone 
per day, or immunosuppressive drug therapy 
following organ transplantation
• Persons with silicosis, diabetes mellitus, chronic 
renal failure, leukemia, or cancer of the head, 
neck, or lung
• Persons who have had a gastrectomy  
or jejunoileal bypass
• Low body weight
• Cigarette smokers and persons who abuse 
drugs or alcohol
• Populations defined locally as having an 
increased incidence of disease due to 
M. tuberculosis, including medically 
underserved, low-income populations
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Diagnosis of LTBI
Currently, the available methods of testing for M. tuberculosis infection are the interferon-gamma 
release assays (IGRAs), such as the QuantiFERON®-TB Gold Plus (QFT-Plus) and the T-SPOT®.TB test 
(T-Spot), and the Mantoux tuberculin skin test (TST). 
Selecting a Test to Detect TB Infection 
In general, using either an IGRA or a TST is acceptable medical and public health practice. However, there 
are a few preferences and special considerations when determining which test to use. 
IGRAs are the preferred method of testing for 
zz Groups of people who might be less likely to return for TST reading and interpretation (for 
example, homeless persons or drug users)
zz People who have received the BCG vaccine
zz People who are likely to be infected with M. tuberculosis and are at a low to intermediate risk of 
progression to TB disease
zz People who are unlikely to be infected with M. tuberculosis (note: persons who are unlikely to be 
infected generally should not be tested for TB)
IGRAs are the preferred method of testing for groups of people who 
have poor rates of return for TST reading and interpretation and for  
people who have received the BCG vaccine.
The TST is the preferred method of testing for children younger than 5 years of age.
The TST is the preferred method of testing  
for children younger than 5 years of age.
Using More than One Type of Test to Detect TB Infection 
Routine testing using both an IGRA and a TST is NOT recommended.  However, there are certain 
situations where results from both tests may be useful:
zz When the initial test is negative and: 
zy The risk for infection, progression to disease, or a poor outcome is high (for example,  
persons living with HIV or children younger than 5 years of age are exposed to a person  
with infectious TB). 
zy There is clinical suspicion for TB disease (for example, signs, symptoms, or radiographic 
evidence suggestive of TB disease) and confirmation of M. tuberculosis infection is desired. 
zz When the initial test is positive and:
zy The person has a low risk of both infection and progression from infection to TB disease.
zy Additional evidence of infection is required to encourage the patient’s acceptance and 
adherence to treatment.
In addition, repeating an IGRA or performing a TST might be useful when the initial IGRA result is 
indeterminate, borderline, or invalid and a reason for testing persists.
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Interferon-Gamma Release Assays
Interferon-gamma release assays (IGRAs) are blood tests that help diagnose M. tuberculosis 
infection by measuring a person’s immune reactivity to M. tuberculosis. White blood cells from most 
people who are infected with M. tuberculosis will release interferon-gamma (IFN-γ) when mixed with 
antigens derived from M. tuberculosis.
IGRAs are used to help diagnose M. tuberculosis infection.
Two IGRAs are currently available in the United States:
zz QuantiFERON®-TB Gold Plus (QFT-Plus)
zz T-SPOT®.TB test (T-Spot) 
Conducting an IGRA
To conduct an IGRA, a patient’s blood samples are mixed with antigens and controls. The antigens, 
testing methods, and interpretation criteria for each of the IGRAs differ (Table 3.2).
Health care workers should be properly trained on how to conduct an IGRA. In general, health care 
workers should read the instructions from the manufacturer and follow the steps below:
zz Confirm arrangements for testing in a qualified laboratory.
zz Arrange for delivery of the blood sample to the laboratory in the time the laboratory specifies to 
ensure testing of samples with viable blood cells.
zz Draw a blood sample from the patient according to the test manufacturer’s instructions (Figure 3.1).
zz Schedule a follow-up appointment for the patient to receive test results.
zz Based on test results, provide follow-up evaluation and treatment as needed. 
Before conducting an IGRA, health care workers should read  
the instructions from the manufacturer and confirm  
arrangements with a qualified laboratory.
Table 3.2 – Differences in currently available IGRAs.
Characteristics QFT-Plus T-Spot
Processing Time Process whole blood  within 16 hours
Process blood cells within  
8 to 32 hours
M. tuberculosis Antigens ESAT-6 and CFP-10 ESAT-6 and CFP-10
Measurement IFN-γ concentration Number of IFN-γ  producing cells (spots)
Possible Results Positive, negative, indeterminate Positive, negative, invalid, borderline
Module 3 – Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 9
How IGRAs Work
Patient blood samples are mixed with antigens (protein substances that can produce an immune 
response) and incubated. The major antigens used, ESAT-6 and CFP-10, are found in M. tuberculosis 
strains. If a person has M. tuberculosis infection, the blood cells in the sample will recognize the antigens 
and release IFN-γ in response. IFN-γ is a protein that the body produces in response to infections. 
Patient blood samples are mixed with antigens  
found in M. tuberculosis strains.
Blood samples are also mixed with control substances. These controls are used for comparison purposes 
to help verify test results and to determine a person’s background level of IFN-γ.
Interpreting IGRA Results 
QFT-Plus results are based on the amount of IFN-γ that is released in response to the M. tuberculosis 
antigens and control substances. T-Spot results are based on the number of IFN-γ producing cells 
(spots) produced. 
QFT-Plus results are based on the amount of IFN-γ released  
in response to the antigens and control substances. T-Spot results  
are based on the number of IFN-γ producing cells (spots) produced.
Laboratories should report both the qualitative and quantitative test results. Qualitative results are 
reported as positive, negative, indeterminate, invalid, or borderline (Table 3.3). Quantitative results 
are reported as numerical values. Quantitative results may be useful for clinical decision making in 
combination with the patient’s risk factors. 
To calculate the test results, laboratories use software provided by the manufacturer. The laboratory 
conducting the analysis of the IGRA will then submit a report of the results back to the health care 
provider who requested the test. 
A medical evaluation and additional tests (such as chest x-rays, sputum smears, and culture) are needed 
to confirm the diagnosis of LTBI or TB disease.
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Table 3.3 – Interpretation of IGRA Results.
IGRA Result Interpretation
Positive M. tuberculosis infection likely
Negative M. tuberculosis infection unlikely, but cannot be 
excluded especially if
1. Patient has signs and symptoms of TB 
2. Patient has a high risk for developing TB disease once  
infected with M. tuberculosis 
Indeterminate (QFT-Plus only) The test did not provide useful information about the likelihood of 
M. tuberculosis infection. Repeating an IGRA or performing a TST 
may be useful.
Invalid or Borderline 
(T-Spot only)
The test did not provide useful information about the likelihood of 
M. tuberculosis infection. Repeating an IGRA or performing a TST 
might be useful.
If the IGRA result is positive, then it is likely that the patient has M. tuberculosis infection. TB disease 
should be ruled out by medical evaluation before LTBI is diagnosed.
Persons who test positive for TB infection should be evaluated for TB disease  
and, if disease is ruled out, they should be considered for LTBI treatment.
If the IGRA result is negative, then the patient is unlikely to have M. tuberculosis infection and may not 
require further evaluation unless he or she has signs and symptoms of TB disease. As with the TST, 
persons who have a negative test result can still have LTBI or TB disease.
If the IGRA result is indeterminate, invalid, or borderline, that means that the test did not provide useful 
information about the likelihood of M. tuberculosis infection. Repeating an IGRA or performing a TST  
may be useful.
Health care workers should consider each IGRA result and its interpretation along with other 
epidemiologic, historical, physical, and diagnostic findings. Regardless of test results, if a patient has signs 
and symptoms of TB disease or if they are at high risk for developing TB disease, they should receive 
further evaluation. 
Negative IGRA results for contacts to persons with infectious TB should be confirmed with a repeat test 
8 to 10 weeks after their last exposure to TB. This is because it can take 2 to 8 weeks after being infected 
with M. tuberculosis for the body’s immune system to mount a response detectable by the test.
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Advantages of IGRAs 
There are advantages and limitations to using IGRAs. Below are some advantages to using an IGRA 
compared to using the TST (Table 3.4).
zz Requires a single patient visit to conduct the test
zz Results can be available within 24 hours
zz Does not cause the booster phenomenon which can happen with repeat TSTs 
zz Previous BCG vaccination does not cause a false-positive result
An advantage of using an IGRA compared to the TST is that it only requires one patient visit to conduct 
the test and results can be available within 24 hours. The TST requires two visits by the patient to obtain 
test results. The patient must come for their first visit to receive the TST and then for a second visit, 48 to 
72 hours later, to have their TST reaction read.
IGRA results can be available in 24 hours.
Since IGRAs are blood tests conducted in a laboratory, the patient is not exposed to the antigens. Thus, 
unlike the TST, there is no booster phenomenon when using an IGRA. Since IGRAs do not cause the 
booster phenomenon, there is no need to use two-step testing. (The booster phenomenon and  
two-step testing are discussed in the TB Testing Program section of this module.)
IGRAs do not cause the booster phenomenon.
The antigens used in IGRAs are not found in the BCG vaccine strains. Therefore, previous vaccination with 
BCG will not cause false-positive results when using an IGRA. 
BCG vaccination does not affect IGRA results.
Table 3.4 – Advantages of using an IGRA compared to using the TST.
IGRA TST
Requires one patient visit to conduct the test Requires at least two patient visits to conduct the test
Results can be available in 24 hours Results are available 48 to 72 hours later
Does not cause booster phenomenon Can cause booster phenomenon
Previous BCG vaccination does not cause false-positive 
result
Previous BCG vaccination may cause false-positive 
result
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Disadvantages and Limitations of IGRAs
There is still limited laboratory and medical experience with using IGRAs. The following are some 
known disadvantages and limitations to using IGRAs:
zz Blood samples must be processed within 8 to 32 hours after collection. 
zz Errors in collecting or transporting blood specimens or in running and interpreting the test can 
decrease the accuracy of IGRAs. 
zz There are limited data on the use of IGRAs to predict who will progress to TB disease in the future.
zz There are limited data on the use of IGRAs in 
zy Children younger than 5 years of age,
zy Persons recently exposed to M. tuberculosis,
zy Immunocompromised persons, and
zy Serial testing.
zz Tests may be expensive.
There is still limited laboratory and medical experience with using IGRAs.
Figure 3.1 Health care worker collecting a blood sample for an IGRA.
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Study Questions 3.1 – 3.4
3.1 What are the steps for conducting an IGRA?
3.2 How are IGRA results interpreted?
3.3 How should a negative IGRA result be interpreted?
3.4 What are four advantages for using IGRAs as compared to the TST?
Answers to study questions are on pages 64–72
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The Mantoux Tuberculin Skin Test (TST)
The TST is used to determine if a person is infected with M. tuberculosis. In this test, a substance called 
tuberculin is injected into the skin. Tuberculin contains antigens used for diagnosing TB infection; it is 
not a vaccine. An antigen is a protein substance that can produce an immune response. Tuberculin is 
made from proteins derived from tubercle bacilli that have been killed by heating. In most people who 
have TB infection, the immune system will recognize the tuberculin because it is similar to the products 
of the tubercle bacilli that caused infection. This will cause a reaction to the tuberculin at the site of the 
injection. Tuberculin used for the skin test is also known as purified protein derivative, or PPD. 
The TST is used to determine if a person is infected with M. tuberculosis.
Tuberculin is not a vaccine.
Administering the TST
The TST is given by using a single dose disposable tuberculin syringe to inject 0.1 ml (5 tuberculin 
units) of liquid tuberculin between the layers of the skin (intradermally), on the forearm (Figure 3.2). 
A tuberculin unit is a standard strength of tuberculin. When giving the TST, institutional guidelines for 
infection control should be followed.
A trained health care worker should examine a patient’s forearm 48 to 72 hours after the tuberculin is 
injected. Health care workers should not ask patients to read their own skin test results. Most people 
with TB infection will have a positive reaction to the tuberculin. The reaction is an area of induration 
(swelling that can be felt) around the site of the injection. The diameter of the indurated area is 
measured in millimeters across the forearm (Figure 3.3); erythema (redness) around the indurated 
area is not measured, because the presence of erythema does not indicate that a person has TB 
infection (Figure 3.4). 
Most people with TB infection have a positive reaction to the tuberculin.
The reaction is an area of induration, or swelling,  
around the site of the injection.
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Figure 3.2 Administering the Mantoux TST.
Figure 3.3 Only the induration is being 
measured. This is CORRECT.
Figure 3.4 The erythema is being measured. 
This is INCORRECT.
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Study Questions 3.5–3.8
3.5 What is the TST used for?
3.6 How is the TST given? 
3.7 With the TST, when is the patient’s arm examined? Select one.
A. Immediately after the tuberculin is injected
B. 2 to 3 hours after the tuberculin is injected
C. 12 to 24 hours after the tuberculin is injected 
D. 48 to 72 hours after the tuberculin is injected
3.8 How is the induration measured? 
Answers to study questions are on pages 64–72
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Interpreting the Reaction
Interpreting a TST reaction depends on the size of the induration and the person’s risk factors for TB 
(Table 3.5).
Interpreting a TST reaction depends on the size of the  
induration and the person’s risk factors for TB.
An induration of 5 or more millimeters is considered a positive reaction for the following people:
zz People living with HIV 
zz Recent contacts of people with infectious TB
zz People with chest x-ray findings suggestive of previous TB disease
zz People with organ transplants 
zz Other immunosuppressed patients (for example, patients on prolonged therapy with 
corticosteroids equivalent to/greater than 15 mg per day of prednisone or those taking  
TNF-alpha antagonists)
An induration of 10 or more millimeters is considered a positive reaction for the following people:
zz People born in countries where TB disease is common, including Mexico, the Philippines, 
Vietnam, India, China, Haiti, and Guatemala, or other countries with high rates of TB
zz People who abuse drugs 
zz Mycobacteriology laboratory workers
zz People who live or work in high-risk congregate settings (for example, nursing homes, homeless 
shelters, or correctional facilities) 
zz People with certain medical conditions that place them at high risk for TB (for example,  
silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain  
intestinal conditions)
zz Children younger than 5 years of age
zz Infants, children, or adolescents exposed to adults in high-risk categories
An induration of 15 or more millimeters is considered a positive reaction for people with no known 
risk factors for TB. However, it is important to remember that testing for TB infection should generally 
be targeted towards high-risk groups, since test results in low-risk groups can be inaccurate. That 
said, any person who has an induration of 15 or more millimeters should receive further evaluation.
An induration of 15 or more millimeters is considered a positive  
reaction for people with no known risk factors for TB.
Most people who have a positive TST reaction will usually have a positive reaction every time they 
are tested, regardless of whether they receive treatment. This is because the TST detects the immune 
response to tuberculin, not the presence of tubercle bacilli in the body.
Thus the TST should not be performed on a person who has a documented history of either a positive 
TST result or treatment for TB disease.
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Interpreting the TST Reaction for Occupational Exposure
For people who may be exposed to TB on the job (such as health care workers and staff of nursing 
homes or correctional facilities), the interpretation of the TST reaction as positive or negative 
depends on 
zz The employee’s individual risk factors for TB
zz The risk of exposure to TB in the person’s job
Therefore, in facilities where TB patients receive care, 10 or more millimeters of induration may be 
considered a positive reaction for employees with no other risk factors for TB. In facilities where the 
risk of exposure to TB is very low, 15 or more millimeters of induration may be considered a positive 
reaction for employees with no other risk factors for TB. 
Table 3.5 – Interpreting the TST reaction.
5 or more millimeters 10 or more millimeters 15 or more millimeters
An induration of 5 or more 
millimeters is considered  
positive for
• People living with HIV 
• Recent contacts of people with 
infectious TB
• People with chest x-ray findings 
suggestive of previous TB 
disease
• People with organ transplants 
• Other immunosuppressed 
patients (for example, patients 
on prolonged therapy with 
corticosteroids equivalent to/
greater than 15 mg per day of 
prednisone or those taking  
TNF-alpha antagonists)
An induration of 10 or more 
millimeters is considered  
positive for
• People born in countries 
where TB disease is common, 
including Mexico, the 
Philippines, Vietnam, India, 
China, Haiti, and Guatemala,  
or other countries with high 
rates of TB  
• People who abuse drugs 
• Mycobacteriology laboratory 
workers
• People who live or work 
in high-risk congregate 
settings (for example, nursing 
homes, homeless shelters, or 
correctional facilities)
• People with certain medical 
conditions that place them at 
high risk for TB (for example, 
silicosis, diabetes mellitus, 
severe kidney disease, certain 
types of cancer, and certain 
intestinal conditions) 
• Children younger than 5 years 
of age
• Infants, children, and 
adolescents exposed to adults 
in high-risk categories
An induration of 15 or more 
millimeters is considered  
positive for
• People with no known risk 
factors for TB
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Study Questions 3.9 – 3.12
3.9 What two factors determine the interpretation of a skin test reaction 
as positive or negative? What additional factor is considered for 
people who may be exposed to TB on the job?
3.10 Five or more millimeters of induration is considered a positive 
reaction for which of the following groups? Select the correct 
answer(s).
A. People living with HIV
B. Recent contacts of people with infectious TB
C. Mycobacteriology workers
D. People with chest x-ray findings suggestive of previous TB disease
3.11 Ten or more millimeters of induration is considered a positive reaction 
for which of the following group(s)? Select the correct answer(s). 
A. Children younger than 5 years of age
B. People who abuse drugs
C. People who live or work in high-risk congregate settings
D. People with organ transplants
3.12 For which group of people is 15 or more millimeters of induration 
considered a positive reaction?
Answers to study questions are on pages 64–72
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Case Study 3.1
Which of the following patients have a positive TST reaction? Select 
the correct answer(s).
A. Mr. West:  
36 years old
HIV infected 
 8 mm of induration
B. Ms. Hernandez: 
26 years old
native of Mexico
7 mm of induration
C. Ms. Jones: 
56 years old
has diabetes
12 mm of induration
D. Mr. Sung: 
79 years old
resident of a nursing home
11 mm of induration
E. Mr. Williams: 
21 years old
no known risk factors
13 mm of induration
F. Ms. Marcos: 
42 years old
chest x-ray findings suggestive of previous TB
6 mm of induration
G. Ms. Rayle: 
50 years old 
husband has pulmonary TB
 9 mm of induration
Answers to case study questions are on pages 73-77
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False-Positive Reactions
The TST is a valuable tool, but it is not perfect. Several factors may cause people to have a positive 
reaction even if they do not have TB infection. This is called a false-positive reaction. 
The causes of false positive reactions may include, but are not limited to, the following:
zz Infection with nontuberculous mycobacteria (NTM) (mycobacteria other than M. tuberculosis)
zz BCG vaccination
zz Administration of incorrect antigen
zz Incorrect measuring or interpretation of the TST reaction
False-positive reactions can be caused by infection with nontuberculous  
mycobacteria, vaccination with BCG, administration of incorrect antigen,  
or incorrect measuring or interpretation of the TST reaction.
Infection with NTM can sometimes cause a false positive reaction to the TST. Another cause of a 
false positive reaction is BCG (bacille Calmette-Guérin), a vaccine for TB disease that is used in many 
countries to prevent severe forms of TB in children. However, BCG is not generally used in the United 
States because the vaccine does not protect all people from getting TB, and it may cause a false-
positive TST reaction. There is no reliable way to distinguish a positive TST reaction caused by BCG 
vaccination from a reaction caused by true TB infection. Thus, when using the TST, people who have 
been vaccinated with BCG should always be further evaluated for LTBI or TB disease as if they were 
not vaccinated with BCG. 
People who have a positive reaction should be further evaluated for LTBI  
or TB disease, even if they were vaccinated with BCG.
A false-positive reaction may also occur if an incorrect antigen is used or when the results are not 
measured or interpreted properly.
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Study Questions 3.13 – 3.14
3.13 Name four factors that may cause false-positive reactions to the TST.
3.14 Is there a reliable way to distinguish a positive tuberculin reaction 
caused by vaccination with BCG from a reaction caused by true  
TB infection?
Answers to study questions are on pages 64–72
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Case Study 3.2
A 30-year-old man who recently immigrated to the United States from 
India is given a TST and found to have 14 millimeters of induration. He 
reports that he was vaccinated with BCG as a child. He also says that his 
wife was treated for pulmonary TB disease last year.
z How should this man’s results be interpreted?
z What factors make it more likely that this man’s positive reaction 
is due to TB infection?
Answers to case study questions are on pages 73-77
False-Negative Reactions
Some people have a negative reaction to the TST even though they have TB infection. This is called a 
false-negative reaction. The reasons for these false-negative reactions may include, but are not limited 
to the following:
zz Anergy
zz Recent TB infection (within the past 8 to 10 weeks)
zz Very young age (younger than 6 months)
zz Recent live-virus measles or smallpox vaccination
zz Incorrect method of giving the TST 
zz Incorrect measuring or interpretation of TST reaction
A common cause of false-negative reactions is anergy. Anergy is the inability to react to skin tests 
because of a weakened immune system. Untreated HIV infection is an important cause of anergy, but 
many other conditions, such as cancer, measles or other viral infections, or even a severe case of TB 
disease, can weaken the immune system and cause anergy. 
 Anergy is the inability to react to skin tests  
because of a weakened immune system.
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Another cause of a false-negative reaction is recent TB infection (infection within the past 8 to 10 
weeks). It can take 2 to 8 weeks after TB infection for the body’s immune system to be able to react to 
tuberculin and for the infection to be detected by the TST. The time between a person’s last exposure 
to infectious TB and when a test can reliably detect infection with M. tuberculosis is referred to as 
the window period. For this reason, it is recommended that contacts of someone with infectious 
TB disease who have a negative test result be retested 8 to 10 weeks after the last time they were in 
contact with the person who has TB disease. 
It takes 2 to 8 weeks after TB infection for the body’s  
immune system to be able to react to tuberculin.
A third cause of false-negative reactions is very young age. Because their immune systems are not yet 
fully developed, children younger than 6 months of age may have a false-negative reaction to the TST.
Because their immune systems are not yet fully developed,  
children younger than 6 months of age may have  
a false-negative reaction to the TST.
Vaccination with live viruses may also lead to a false-negative reaction. The Advisory Committee on 
Immunization Practices recommends that skin testing be done on either the same day as vaccination 
with live-virus measles vaccine or 4 to 6 weeks after vaccination to prevent possible false-negative 
reactions. Also, skin testing should not be done until at least 1 month after a smallpox vaccination.
A false-negative reaction may also occur when the TST is given incorrectly or the results are not 
measured or interpreted properly. 
Both false-positive and false-negative reactions to the TST are summarized in Table 3.6.
Any patient with symptoms of TB should be evaluated for TB disease, regardless of his or her TST 
reaction. In fact, people with symptoms of TB should be evaluated for TB disease right away, at the same 
time that the TST is given. TB symptoms and the diagnosis of disease are discussed later in this module.
Any patient with symptoms of TB should be evaluated for TB disease,  
regardless of his or her skin test reaction.
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Table 3.6 – False-positive and false-negative reactions to the TST.
Type of Reaction Possible Cause People at Risk
False-positive
Nontuberculous mycobacteria (NTM) People infected with NTM
BCG vaccination People vaccinated with BCG
Administering incorrect antigen Any person being tested
Incorrect interpretation of TST result Any person being tested
False-negative
Anergy
HIV-infected people, other people with 
weakened immune systems, severe 
TB disease, and some viral illness (e.g., 
measles and chicken pox)
Recent TB infection People infected with M. tuberculosis within the past 8 to 10 weeks
Very young age Children younger than 6 months of age
Recent live-virus measles or small pox 
vaccination
Any person who has recently received a 
live-virus vaccination
Incorrect method of giving TST Any person being tested
Incorrect interpretation of TST Any person being tested
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Study Questions 3.15 – 3.18
3.15 Name six factors that can cause false-negative reactions to the TST.
3.16 What is anergy?
3.17 After TB germs have been transmitted to someone, how long does it 
take before TB infection can be detected by the TST? Select one.
A. 3 to 5 days
B. 1 week
C. 2 to 8 weeks
D. 12 to 14 weeks
3.18 What should be done if a patient has a negative TST result, but has 
symptoms of TB disease?
Answers to study questions are on pages 64–72
Module 3 – Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 27
Case Study 3.3
Mr. Bell comes to the TB clinic for a TST. He believes that he has been 
exposed to TB, and he knows he is at high risk for TB because he is 
HIV infected. He is given a TST, and his reaction is read 48 hours later 
as 0 millimeters of induration.
z What are three ways to interpret this result?
Answers to case study questions are on pages 73-77
TB Testing Programs
Many residential facilities, health care facilities, and other settings have TB testing programs. This  
means that employees and residents are periodically given TSTs or IGRAs. The purposes of the testing 
programs are to 
zz  Identify people who have LTBI and possibly TB disease, so that they can be given treatment  
as needed
zz Determine whether TB is being transmitted in the facility
Certain facilities have TB testing programs, in which employees  
and residents are periodically given TSTs or IGRAs.
In a TB testing program, employees or residents are TB tested when they start their job or enter the 
facility. If they are using a TST, this is called the baseline skin test. If they have a negative test result, the 
employee or resident may be retested at regular intervals thereafter. In some facilities, repeat testing 
should be done at least once a year. 
In a TB testing program, employees or residents are tested for TB  
when they start their job or enter the facility; in some facilities,  
repeat testing is done at regular intervals thereafter.
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Employees or residents whose test results convert from negative to positive between testing intervals 
may have become infected with M. tuberculosis. These test conversions may indicate that TB is being 
transmitted in the facility. People with test conversions are at high risk of developing TB disease if they 
were infected with M. tuberculosis relatively recently. In order to detect TB transmission and identify 
people who have test conversions, it is important to keep accurate information on every employee’s 
baseline test, and subsequent tests. 
In order to detect TB transmission and identify people  
who have test conversions, accurate information must be  
obtained for every employee’s tests.
For most health care personnel, annual TB testing is not recommended unless there is an occupational 
risk, known exposure, or ongoing transmission.  For more information on TB testing programs at health 
care and residential facilities, please refer to Module 5, Infectiousness and Infection Control. 
The Booster Phenomenon
One factor that can affect the accuracy of the baseline TB skin test is the booster phenomenon. The 
booster phenomenon happens because in some people who have TB infection, the ability to react 
to tuberculin decreases over time. When these people are skin tested many years after they become 
infected with M. tuberculosis, they may have a negative reaction. However, if they are tested again 
within a year of the first test, they may have a positive reaction. This is because the first skin test “jogged 
the memory” of the immune system, boosting its ability to react to tuberculin. It may appear that these 
people were infected between the first and second skin tests; however, the second reaction is actually a 
boosted reaction (due to TB infection that occurred a long time ago). The booster phenomenon occurs 
mainly among older adults. Figure 3.5 illustrates the booster phenomenon. 
The booster phenomenon can affect the accuracy of the skin test.
The booster phenomenon happens when a skin test boosts  
the ability of the immune system to react to tuberculin.
IGRAs do not boost subsequent test results because, unlike the TST, the patient is not exposed to the 
M. tuberculosis antigens. However, the TST can boost a subsequent IGRA. Therefore, if a person will be 
tested with both the TST and an IGRA, it is recommended to conduct the IGRA either before or at the 
same time as the TST.
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A person becomes infected with M. tuberculosis.
The person is skin tested years later. As the years pass, the 
person’s ability to react to 
tuberculin lessens. 
The person has a negative reaction  
because he or she has a lessened ability  
to react to tuberculin. 
However, this skin test “jogs the  
memory” of the immune system  
to recognize and react to tuberculin.
The person is skin tested again,  
within 1 year. For this example,  
we assume that the person  
was NOT exposed to TB during this time.
The person has a positive reaction. This is 
a boosted reaction due to TB infection that 
occurred a long time ago, not during the 
time between the two skin tests.
Occurs mainly in previously 
infected, older adults whose 
ability to react to tuberculin 
has decreased over time.
Figure 3.5 The booster phenomenon with the TST.
The booster phenomenon can present a problem in TB testing programs. This is because a negative 
reaction to the baseline skin test, followed by a positive reaction to a subsequent skin test that is given 
up to a year later, may be caused by either
zz Recent TB infection in a person who was NOT infected at the time of the baseline skin test, or 
zz A boosted reaction in a person who WAS already infected before the baseline skin test.
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Two-Step Testing with the TST
To avoid misinterpretation, a strategy called two-step testing has been developed for telling the 
difference between boosted reactions and reactions caused by recent infection.  Two-step testing 
should be used for the initial TB skin testing of persons who will be retested periodically.
Two-step testing is a strategy for telling the difference between  
boosted reactions and reactions caused by recent infection.
Two-step testing is not required for IGRAs because IGRA testing does not boost subsequent test results.
If a person has a negative reaction to an initial skin test, he or she is given a second test 1 to 3 weeks later.
zz If the reaction to the second test is positive, it probably is a boosted reaction (due to TB 
infection that occurred a long time ago).
zz If the reaction to the second test is negative, the person is considered uninfected. In this person, 
a positive reaction to a skin test given later on will probably be due to recent infection and be 
considered a skin test conversion.
Because two-step testing provides accurate information about an employee’s baseline skin test reaction, 
it is used in many TB testing programs for employees when they start their job. In particular, two-step 
testing is often used in hospitals and nursing homes. The procedure for two-step testing is shown in 
Figure 3.6. 
Two-step testing is used in many TB testing programs  
for skin testing employees when they start their job.
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NEGATIVE
NEGATIVE
Reaction
Reaction
POSITIVE
POSITIVE
Retest 1–3 weeks later 
Retesting not necessary
Person probably 
has TB infection 
Person probably 
does NOT have 
TB infection 
The reaction is considered a 
boosted reaction (due to 
TB infection that  occurred 
a long time ago)
Baseline Skin Test
Figure 3.6 Two-step testing with the TST.
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Study Questions 3.19–3.22
3.19 What is the booster phenomenon?
3.20 What is the purpose of two-step testing?
3.21 In what situation is two-step testing used? Select one.
A. When testing people who have HIV/AIDS
B. When testing new employees in a TB testing program
C. When testing people who have diabetes
D. When any patient’s first TST reaction is positive
3.22 How is two-step testing done?
Answers to study questions are on pages 64-72
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Case Study 3.4
Ms. Wilson is a 60-year-old nurse. When she started a job at the local 
hospital, she was given a TST, her first test in 25 years. Her reaction 
was read 48 hours later as 0 millimeters of induration. Six months 
later, she was retested as part of the TB testing program in the unit 
where she works. Her skin test reaction was read 48 hours later as  
11 millimeters of induration.
z What are two ways to interpret this result?
Answers to case study questions are on pages 73-77
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3
MODULE
Diagnosis of TB Disease
The key to diagnosing TB is for clinicians to “think TB” when they see a patient with symptoms of the 
disease or abnormal chest x-ray findings. Because TB is not as common as it was many years ago in the 
United States, many clinicians do not consider the possibility of TB when making diagnoses for patients 
who have symptoms of TB. When this happens, the diagnosis of TB may be delayed or even overlooked, 
and the patient will remain ill and possibly infectious.
Anyone with symptoms of TB or anyone found to have a positive TST or IGRA result should be 
medically evaluated for TB disease. 
Anyone with symptoms of TB or a positive TST or IGRA result  
should be medically evaluated for TB disease.
There are five components for conducting a complete medical evaluation for diagnosing TB disease. 
1. Medical history 
2. Physical examination 
3. Test for TB infection 
4. Chest x-ray
5. Bacteriological examinations 
The Medical History
A medical history is the part of a patient’s life history that is important for diagnosing and treating the 
patient’s medical condition. It includes social, family, medical, and occupational information about  
the patient.
To obtain a medical history, the clinician should ask whether the patient has:
zz Any symptoms of TB disease
zz Been exposed to a person with infectious TB or has risk factors for exposure to TB
zz Risk factors for developing TB disease
zz Had LTBI or TB disease before
Clinicians should suspect the possibility of TB disease in patients with any of these factors.
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Symptoms of TB disease
People with TB disease may or may not have symptoms. However, most patients with TB disease have 
one or more symptoms that led them to seek medical care. Occasionally, TB is discovered during a 
medical examination for an unrelated condition (for example, when a patient is given a chest x-ray 
before undergoing surgery). Usually, when patients do have symptoms, the symptoms have developed 
gradually, and have been present for weeks or even months. General symptoms of TB disease include
zz Fever
zz Chills
zz Drenching night sweats
zz Weight loss
zz Appetite loss
zz Fatigue 
zz Malaise 
Pulmonary TB disease usually causes one or more of the following symptoms:
zz A cough lasting for 3 or more weeks
zz Chest pain when breathing or coughing
zz Coughing up sputum (phlegm from deep in the lungs) or blood
People with TB disease may or may not have symptoms.
The symptoms of extrapulmonary TB disease depend on the part of the body that is affected by the 
disease. For example, TB of the spine may cause pain in the back; TB of the kidney may cause blood  
in the urine. 
The symptoms of extrapulmonary TB disease depend  
on the part of the body that is affected by the disease.
All of these symptoms may be caused by other diseases, but they should prompt the clinician to 
suspect the possibility of TB disease. 
Exposure to TB
Another important part of the medical history is asking the patient about his or her exposure to TB. 
Patients should be asked whether they have spent time with someone who has infectious TB. Some 
people may have been exposed to TB in the distant past, when they were children. Others may have 
been exposed more recently. 
Some people may have been exposed to TB in the distant past, when  
they were children. Others may have been exposed more recently.
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Anyone who has been exposed to TB may have TB infection. Some people become infected with  
M. tuberculosis without knowing that they were exposed to it. The risk of being exposed to TB is higher 
for some people. It is important to consider demographic factors (for example, country of birth, travel to 
a country where TB is common, age, ethnic or racial group, or occupation) that may increase the patient’s 
risk for exposure to TB. 
Risk factors for developing TB disease
The third part of the medical history is checking for the patient’s risk factors for developing TB disease, 
including other medical conditions, such as HIV infection, use of TNF-alpha antagonists, or diabetes, 
which can increase the risk of LTBI progressing to TB disease. All patients who do not know their current 
HIV status should be referred for HIV counseling and testing.
Some conditions increase the risk that TB infection will progress to disease.
For more information on factors and medical conditions that can increase the risk of patients developing 
TB disease, see the Targeted Testing section of this module.
Previous TB infection or TB disease
During the medical history, the clinician should ask the patient whether he or she has ever been 
diagnosed with or treated for TB infection or disease.
zz Patients known to have a positive TST or IGRA result probably have TB infection. If they were 
infected within the past 2 years, they are at high-risk for developing TB disease. 
zz Patients who have had TB disease before should be asked when they had the disease and how 
the disease was treated. 
The clinician should ask the patient whether he or she has ever  
been diagnosed with or treated for TB infection or disease.
Clinicians may also contact the local health department for information about whether a patient has 
received TB treatment in the past. If the prescribed treatment regimen was inadequate or if the patient 
did not follow the recommended treatment, the TB disease may come back, and it may be resistant to 
one or more of the drugs used.
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Physical Examination
A physical examination is an essential part of the evaluation of any patient. It cannot confirm or rule out 
TB disease, but it can provide valuable information about the patient’s overall condition and factors that 
may affect how TB disease is treated if it is diagnosed.
Testing for TB Infection
Currently, there are two methods available for diagnosing TB infection in the United States:
zz Interferon-gamma release assays (IGRAs)
zz Mantoux tuberculin skin test (TST)
Patients with symptoms of TB disease are sometimes evaluated by an IGRA or a TST to detect infection 
with TB. However, some patients with TB disease may have a negative IGRA or TST result. Patients 
with symptoms should always be evaluated for TB disease, regardless of their IGRA or TST results. 
Furthermore, clinicians should not wait for IGRA or TST results before starting other diagnostic tests for 
patients with symptoms of TB disease. Instead, the clinician should order an IGRA or place a TST at the 
same time as the other steps in the diagnosis of TB disease.
Patients with symptoms of TB disease should always be evaluated  
for TB disease, regardless of their TST or IGRA results.
Study Question 3.23
3.23 What are the five components for conducting a medical 
evaluation for diagnosing TB disease?
Answers to study questions are on pages 64-72
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Study Questions 3.24 – 3.26
3.24 What parts of a patient’s medical history should lead a clinician to 
suspect the possibility of TB?
3.25 Which of the following are symptoms of TB disease? Select the 
correct answer(s).
A. Fever
B. Weight loss
C. Runny nose
D. Cough lasting 3 or more weeks
3.26 For patients with symptoms of TB disease, should clinicians wait 
for TST or IGRA results before starting other diagnostic tests?
Answers to study questions are on pages 64-72
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The Chest X-Ray
The chest x-ray, or radiograph, is useful for diagnosing TB disease because pulmonary TB is the most 
common form of the disease. Usually, when a person has TB disease in the lungs, the chest x-ray appears 
abnormal (Figure 3.7). It may show infiltrates (collections of fluid and cells in the tissues of the lung) or 
cavities (hollow spaces within the lung that may contain many tubercle bacilli).
Chest x-rays are useful for diagnosing TB disease because  
pulmonary TB is the most common form of the disease.
Figure 3.7 Abnormal chest x-ray. Arrows point to lower lobe cavity.
The purposes of the chest x-ray are to 
zz Help rule out the possibility of pulmonary TB disease in a person who has a positive TST  
or IGRA result
zz Check for lung abnormalities in people who have symptoms of TB disease
The results of a chest x-ray, however, cannot confirm that a person has TB disease. A variety of illnesses 
may produce abnormalities that resemble TB on a chest x-ray. Although an abnormality on a chest 
x-ray may lead a clinician to suspect TB, only a bacteriologic culture that is positive for M. tuberculosis 
confirms that a patient has TB disease. Moreover, a chest x-ray cannot detect TB infection.
The results of a chest x-ray cannot confirm that a person has TB disease.
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In persons living with HIV, pulmonary TB disease may have an unusual appearance on the chest x-ray. 
The chest x-ray may even appear entirely normal.
In HIV-infected patients, pulmonary TB may have  
an unusual appearance on the chest x-ray.
A chest x-ray may be used to rule out the possibility of pulmonary TB in a person who has had a positive 
TST or IGRA result and no symptoms of disease.
Study Questions 3.27 – 3.28
3.27 Name two purposes of the chest x-ray.
3.28 Can the results of a chest x-ray confirm that a person has TB disease? 
Why or why not?
Answers to study questions are on pages 64-72
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The Bacteriologic Examination
Clinical specimens (for example, sputum or urine) are examined and cultured (grown) in the laboratory 
for the bacteriologic examination. TB bacteriologic examination is done in a laboratory that specifically 
deals with M. tuberculosis and other mycobacteria (a mycobacteriology laboratory). The bacteriologic 
examination has five parts:
zz Specimen collection
zz Examination of smears for acid-fast bacilli 
zz Direct detection of M. tuberculosis in the specimen using a nucleic acid amplification test
zz Specimen culturing and identification of growth
zz Drug susceptibility testing 
A bacteriologic examination is done in a laboratory that specifically  
deals with M. tuberculosis and other mycobacteria.
Specimen collection
Specimens that will be sent to the laboratory can be obtained in several ways. Usually, patients who 
are suspected of having pulmonary TB disease simply cough up sputum (phlegm from deep in the 
lungs) into a sterile container for processing and examination (Figure 3.8). This is the least expensive and 
easiest procedure. A health care worker should coach and directly supervise the patient when sputum is 
collected. Patients who are not supervised are not always successful in providing an adequate specimen, 
especially in their first attempt. The volume and quality of the specimen are critical for ensuring 
bacteriological examination is successful.
Patients suspected of having pulmonary TB disease may  
cough up sputum, which is collected in a sterile container  
for processing and examination.
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Figure 3.8 A TB patient has coughed up sputum and is depositing 
it into a sterile container. The patient is sitting in a special sputum 
collection booth that prevents the spread of tubercle bacilli.
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Patients should have at least three consecutive sputum specimens examined, each collected in 8 to 24-
hour intervals. At least one should be collected early in the morning. 
If a patient cannot cough up sputum on his or her own, other techniques can be used to obtain a 
specimen. An induced sputum sample can be obtained by having the patient inhale a saline (salt water) 
mist, which causes the patient to cough deeply. Induced specimens are often clear and watery; they 
should be labeled “induced specimen” so that they will not be confused with saliva. Laboratories will not 
accept saliva as a specimen.
For an induced sputum sample, the patient inhales  
a saline mist, causing him or her to cough deeply.
Another procedure, bronchoscopy, can be used to obtain pulmonary secretions or lung tissue. In this 
procedure, an instrument called the bronchoscope is passed through the mouth and airways directly 
into the diseased portion of the lung, and some sputum or lung tissue is removed. Bronchoscopy  
should be used only when patients cannot cough up sputum on their own and an induced specimen 
cannot be obtained.
A bronchoscopy is done to obtain  
pulmonary secretions or lung tissue.
A fourth procedure, gastric washing, involves inserting a tube through the patient’s nose and passing 
it into the stomach. The purpose is to get a sample of gastric fluids that contains sputum that has been 
coughed into the throat and then swallowed. Gastric washings are done in the morning because 
patients usually swallow sputum during the night. This procedure is usually used only when patients 
cannot cough up sputum on their own, and an induced specimen cannot be obtained. Gastric washings 
are often used for obtaining samples from children. Most children produce little or no sputum when 
they cough, or are too young to follow instructions.
For gastric washing, a tube is inserted through the patient’s  
nose and passed into the stomach to collect a sample of  
sputum that has been coughed into the throat and then swallowed.
It is very important for health care workers to use infection control precautions to control the spread of 
tubercle bacilli during these procedures and any other procedures that may cause persons who have 
pulmonary TB disease to cough. This is discussed further in Module 5, Infectiousness and Infection Control.
Health care workers should use precautions to control the  
spread of tubercle bacilli during sputum collection procedures.
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In patients who have extrapulmonary TB disease, specimens other than sputum may be obtained. The 
specimen obtained from these patients depends on the part of the body that is affected. For example, 
urine samples are obtained from patients suspected of having TB disease of the kidney, and fluid samples 
are obtained from the area around the spine in patients suspected of having TB meningitis (TB disease in 
the membranes surrounding the brain and spinal cord).
In patients with extrapulmonary TB disease, specimens are obtained  
in various ways, depending on the part of the body that is affected.
The methods of obtaining a sputum specimen are summarized in Table 3.7.
Table 3.7– Methods of obtaining a sputum specimen.
 Method Description Advantages Disadvantages
Coughing up sputum
Patient coughs up sputum Inexpensive
Easy to do
Patient may not be able to 
cough up sputum on his 
or her own, or may spit up 
saliva instead of sputum
Inducing sputum
Patient inhales a saline 
mist, causing him or her  
to cough deeply
Easy to do Specimens may be watery 
and may be confused with 
saliva (should be labeled 
“induced specimen”)
Requires special 
equipment
Bronchoscopy
Bronchoscope is passed 
through the mouth and 
airways directly into the 
diseased portion of the 
lung, and some fluid or 
lung tissue is removed
Useful for obtaining 
sputum when coughing 
or inducing sputum does 
not work
Expensive and invasive 
procedure
Requires special 
equipment
Must be done by a 
specialized physician in a 
hospital or clinic
Gastric washing
Tube is inserted through 
the patient’s nose and 
passed into the stomach 
to get a sample of gastric 
secretions that contain 
sputum that has been 
coughed into the throat 
and then swallowed
Useful for obtaining 
samples in children, who 
usually produce little or no 
sputum when they cough
Must be done as soon as 
patient wakes up in the 
morning; patient may be 
required to stay in hospital
Can be uncomfortable for 
the patient
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Case Study 3.5
Mr. Lee has a cough and other symptoms of TB disease, and he is 
evaluated with a chest x-ray. However, he is unable to cough up any 
sputum on his own for the bacteriologic examination.
z What should be done?
Answers to case study questions are on pages 73-77
Examination of AFB smears
Before the specimen is examined under a microscope, it may undergo processing to break up the sample 
and kill other organisms that may be present. A sample is smeared onto a glass slide and stained with dyes. 
This is called a smear. Then laboratory personnel use a microscope to look for acid-fast bacilli (AFB) on the 
smear (Figure 3.9). AFB are bacteria that stay stained even after they have been washed in an acid solution. 
Tubercle bacilli are one kind of AFB.
Specimens are smeared onto a glass slide and stained so that  
they can be examined for acid-fast bacilli (AFB) under a microscope.
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Figure 3.9 AFB smear. In this photograph, the AFB (stained red) are tubercle bacilli.
When AFB are seen in a smear, they are counted. There is a system for reporting the number of AFB  
that are seen at a certain magnification. According to the number of AFB seen, the smears are classified 
as 4+, 3+, 2+, or 1+. In smears classified as 4+, 10 times as many AFB were seen as in smears classified as 
3+; in 3+ smears, 10 times as many as in 2+ smears; and in 2+ smears, 10 times as many as in 1+ smears.
When AFB are seen in a smear, they are counted and  
classified according to the number of AFB seen.
Smears that are classified as 4+ and 3+ are considered strongly positive; 2+ and 1+ smears are considered 
moderately positive. If very few AFB are seen, the smear is classified by the actual number of AFB seen (no 
plus sign). For example, if only 2 AFB were seen in the entire smear, the smear is classified as “2 AFB seen.” 
Smears classified in this way are considered weakly positive, and the smear should be repeated. Finally, if 
no AFB are seen, the smear is called negative. But a negative smear does not rule out the possibility of TB 
because there can be AFB in the smear that were not seen.
A negative smear does not rule out the possibility of TB  
because there can be AFB in the smear that were not seen.
It takes only a few hours to prepare and examine a smear. Therefore, the results of the smear examination 
should be available to the clinician within 1 day.
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The results of the smear examination can be used to help determine the infectiousness of the patient. 
Patients who have many tubercle bacilli in their sputum have a positive smear. Patients who have positive 
smears are considered infectious because they can cough many tubercle bacilli into the air. (This is 
discussed in more detail in Module 5, Infectiousness and Infection Control.) However, because AFB are not 
always tubercle bacilli, patients who have positive smears do not necessarily have TB. Furthermore, as 
mentioned previously, patients who have negative smears may have TB.
The results of the smear examination can be used to  
help determine the infectiousness of the patient.
The classification of smears is summarized in Table 3.8.
 
Table 3.8 – Smear classifications and results.
Classification of Smear Smear Result Infectiousness of Patient
4+ Strongly positive Probably very infectious
3+ Strongly positive Probably very infectious
2+ Moderately positive Probably infectious
1+ Moderately positive Probably infectious
Actual number of AFB seen 
(no plus sign) 
Weakly positive Probably infectious
No AFB seen Negative May not be infectious*
*The criteria for determining whether a patient may be considered noninfectious are discussed in Module 5, Infectiousness 
and Infection Control.
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Study Questions 3.29 – 3.31
3.29 What are the four ways to collect sputum specimens? Indicate 
which procedure is the least expensive and easiest to perform.
3.30 What do laboratory personnel look for in a smear?
A. Acid-fast bacilli
B. White blood cells
C. Fast-moving bacilli
D. Drug-resistant bacilli
3.31 What does a positive smear indicate about a patient’s 
infectiousness?
Answers to study questions are on pages 64-72
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Case Study 3.6
Ms. Thompson gave three sputum specimens, which were sent 
to the laboratory for smear examination and culture. The smear 
results were reported as 4+, 3+, and 4+.
z What do these results tell you about Ms. Thompson’s diagnosis and 
her infectiousness?
Answers to case study questions are on pages 73-77
Case Study 3.7
Mr. Sagoo has symptoms of TB disease and a cavity on his chest 
x-ray, but all of his sputum smears are negative for acid-fast bacilli.
z Does this rule out the diagnosis of pulmonary TB disease?
z Why or why not?
Answers to case study questions are on pages 73-77
Module 3 – Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease50
Direct detection of M. tuberculosis in the specimen by nucleic acid amplification test
Nucleic acid amplification (NAA) tests can be used to rapidly detect M. tuberculosis from sputum 
specimens. (See Figure 3.10). NAA tests, including polymerase chain reaction (PCR) and other methods, 
rapidly identify the microorganisms in the specimen by amplifying (copying) DNA and RNA segments. NAA 
testing should be performed on at least one respiratory specimen from a patient with signs and symptoms 
of pulmonary TB for whom a diagnosis of TB is being considered, and for whom the test result would alter 
case management or TB control activities. 
Nucleic acid amplification (NAA) tests can be used to  
detect M. tuberculosis from sputum specimens.
A patient can be presumed to have TB if he or she has a positive NAA test with an AFB positive smear. 
If a patient has a negative NAA test with an AFB positive smear, he or she may have a nontuberculous 
mycobacteria (NTM) infection. NAA test results can help guide clinicians’ decisions for patient therapy and 
isolation; however, NAA tests do not replace the need for AFB smear, culture, or clinical judgment.
NAA test results can help guide clinicians’ decisions for patient  
therapy and isolation; however, NAA tests do not replace  
the need for AFB smear, culture, or clinical judgment.
For more information about NAA tests, refer to the CDC’s Updated Guidelines for the Use of Nucleic Acid 
Amplification Tests in the Diagnosis of Tuberculosis, available from the CDC website (www.cdc.gov/tb). 
Xpert MTB/RIF Assay
The Xpert MTB/RIF assay is an NAA test that simultaneously detects M. tuberculosis complex and resistance 
to rifampin, one of the most effective drugs used to treat TB. 
To conduct the Xpert MTB/RIF assay, a sputum sample is mixed with a sterilizing reagent that is provided 
with the assay, and a cartridge containing the mixture is placed in the GeneXpert machine. Results from 
the test are available in less than 2 hours.
The Xpert MTB/RIF assay simultaneously detects 
Mycobacterium tuberculosis complex and  
resistance to rifampin in less than 2 hours.
Results that are positive for M. tuberculosis complex and for rifampin resistance indicate that the bacteria 
have a high probability of resistance to rifampin. This result should be confirmed by additional rapid testing. 
If rifampin resistance is confirmed, rapid molecular testing for drug resistance to both first-line and second-
line drugs should be performed so that an effective treatment regimen can be selected. Growth-based 
drug susceptibility testing should be performed as well. Growth-based susceptibility testing is discussed in 
more detail on page 57 of this module.
Results that are positive for M. tuberculosis complex, but negative for rifampin resistance mean that the 
bacteria are probably susceptible to rifampin. However, all tests that are positive for M. tuberculosis complex 
should have growth-based drug susceptibility testing to first-line TB drugs. 
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Results that are positive for M. tuberculosis complex and indeterminate for rifampin resistance mean that 
the test could not accurately determine if the bacteria are resistant.
As with other NAA tests, the Xpert MTB/RIF assay should be interpreted along with clinical, radiographic, 
and other laboratory findings. The Xpert MTB/RIF assay does not replace the need for AFB smear 
microscopy, culture for mycobacteria, growth-based drug susceptibility testing, and genotyping. 
Providers and laboratories need to ensure that patient specimens are available for all recommended 
mycobacterial testing.
As with other NAA tests, the Xpert MTB/RIF assay should be interpreted  
along with clinical, radiographic, and other laboratory findings.
For more information on the Xpert MTB/RIF assay, refer to the CDC guidelines, Availability of an Assay 
for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its 
Use — United States, 2013, available from the CDC website (www.cdc.gov/tb). 
Culturing and identifying growth from the specimen 
Culturing the specimen means growing the mycobacteria on solid or in liquid media (Figure 3.11). 
When the mycobacteria have formed colonies (groups), or when there is sufficient growth in the 
liquid media, they can be identified. All specimens should be cultured, regardless of whether the 
smear is positive or negative.
All specimens should be cultured, regardless of  
whether the smear is positive or negative.
Culturing the specimen is necessary to determine if it contains M. tuberculosis and to confirm 
a diagnosis of TB disease. Additionally, culture is necessary to perform further drug susceptibility 
testing and genotyping.
Culturing the specimen is necessary to determine if it contains  
M. tuberculosis and to confirm a diagnosis of TB disease.
In some instances, patients are diagnosed with TB disease on the basis of their clinical presentation 
(i.e., signs and symptoms, response to treatment), even if their culture is negative. 
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Figure 3.10 NAA test kit.
Figure 3.11 Colonies of M. tuberculosis growing on solid media.
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The first procedure in culturing the specimen is to detect the growth of the mycobacteria. Mycobacteria 
grow very slowly. When solid media are used to culture the specimen, it can take as long as 3 to 6 weeks 
for the growth of the mycobacteria to be detected. However, rapid culturing methods that involve liquid 
media can decrease this time to 4 to 14 days.
The first procedure in culturing the specimen  
is to detect the growth of the mycobacteria.
The second procedure is to identify the organism that has grown in the culture. All types of mycobacteria 
will grow in solid or liquid media. For this reason, laboratory tests must be done to determine whether the 
organism is M. tuberculosis or one of the nontuberculous mycobacteria. Nucleic acid probes can rapidly 
identify the type of mycobacteria present in the specimens in 2 to 4 hours. Thus, using liquid media and 
nucleic acid probes, it is usually possible to culture and to identify M. tuberculosis within three weeks.
The second procedure is to identify  
the organism that has grown.
When M. tuberculosis is identified in a patient’s culture, the patient is said to have a positive culture for  
M. tuberculosis. A positive culture for M. tuberculosis, also called an M. tuberculosis isolate, confirms the 
diagnosis of TB disease.
A positive culture for 
M. tuberculosis confirms the diagnosis of TB disease.
When M. tuberculosis is NOT identified in a patient’s culture, the patient is said to have a negative culture for 
M. tuberculosis. A negative culture does not necessarily rule out the diagnosis of TB disease; as mentioned 
earlier, some patients with negative cultures are diagnosed with TB disease on the basis of their clinical 
presentation (i.e., signs and symptoms, response to treatment).
Follow-up bacteriological examinations are important for assessing the patient’s infectiousness and 
response to treatment. Specimens should be obtained monthly until 2 consecutive specimen cultures 
are negative. Culture conversion is the most important objective measure of response to treatment.
Laboratories should report positive results on smears and cultures within 24 hours by telephone or fax to 
the primary health care provider and to the state or local TB control program, as required by law. Out-of-
state laboratories who receive referral specimens must contact the health care provider in the patient’s 
state of origin. Follow-up results may be reported by mail. It is the responsibility of the primary health care 
provider to promptly report all suspected or confirmed cases of TB to the state or local health department, 
unless state laws indicate otherwise. This will ensure that a contact investigation can be initiated quickly 
to interrupt the potential ongoing transmission.
The differences between sputum smears and cultures are summarized in Table 3.9.
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Table 3.9 – Differences between sputum smears and cultures.
Features Smears Cultures
Equipment needed Microscope, glass slides,  
special dyes
Incubators, biosafety cabinet, culture plates or 
tubes, culture media
Time needed to make report 1 day 4 days to 8 weeks (depending on method used 
and how quickly the organism grows)
Basis of procedure Looking for AFB on slide under 
microscope
Growth and identification of tubercle bacilli or 
other mycobacteria on culture media
Significance of a negative 
report
Patient is less likely to be 
infectious
Does not rule out TB disease 
(culture may be positive)
No live tubercle bacilli found in the specimen 
Does not rule out TB disease (live tubercle 
bacilli may be in other specimens or in the 
patient)
Significance of a positive 
report
Patient is more likely to be 
infectious (if AFB are tubercle 
bacilli)
AFB could be nontuberculous 
mycobacteria
Confirms diagnosis of TB disease
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Criteria for Reporting TB Cases
All 50 states, the District of Columbia, New York City, Puerto Rico, and seven other 
jurisdictions in the Pacific and the Caribbean report TB cases to the federal Centers for 
Disease Control and Prevention (CDC) using a standard case reporting mechanism called 
the Report of Verified of Case of Tuberculosis (RVCT). Each reported TB case is checked to 
make sure that it meets certain criteria. All cases that meet the criteria, called verified TB 
cases, are counted each year.
Cases that meet one of these four sets of criteria are counted as verified TB cases:
1. The patient has a positive culture for M. tuberculosis.
or
2. The patient has a positive NAA test for M. tuberculosis.*
or
3. The patient has a positive smear for AFB, but a culture has not been or cannot be 
obtained or is falsely negative or contaminated.
or
4.  If in the absence of laboratory confirmation, the patient meets all of the following 
criteria:
zz A positive TST or IGRA,
zz Other signs and symptoms of TB disease (e.g., abnormal chest x-ray, fever, night 
sweats, cough, weight loss, hemoptysis),
zz Treatment with two or more anti-TB drugs, and 
zz A completed diagnostic evaluation. 
In addition, cases that do not meet any of these sets of criteria (for example, a patient 
who is anergic and has a negative culture for M. tuberculosis but who has signs and 
symptoms of TB disease) may be counted as a verified TB case if a health care provider 
has reported the case and decided to treat the patient for TB disease.
*Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species. However, for surveillance 
purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used 
according to the approved product labeling on the package insert, or a test produced and validated in accordance with 
applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.
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Drug susceptibility testing
For all patients, drug susceptibility tests should be done when the patient is first found to have a positive 
culture for M. tuberculosis (that is, the first isolate of M. tuberculosis). Drug susceptibility tests are done to 
determine which drugs will kill the tubercle bacilli that are causing disease in a particular patient. Tubercle 
bacilli that are killed by a particular drug are said to be susceptible to that drug, whereas those that can 
grow even in the presence of a particular drug are said to be resistant to that drug. The drug susceptibility 
pattern of a strain of tubercle bacilli is the list of drugs to which the strain is susceptible and to which it is 
resistant. The initial isolate should be tested for resistance to the first-line anti-TB drugs: rifampin, isoniazid, 
ethambutol, and pyrazinamide.   
Drug susceptibility tests should be done when a patient 
 is first found to have a positive culture for M. tuberculosis.
Drug susceptibility tests determine which drugs will kill  
the tubercle bacilli that are causing disease in a particular patient.
Drug-resistant TB is mono-resistant if the tubercle bacilli are resistant to one TB treatment drug, or  
poly-resistant if resistant to at least two TB drugs (but not both isoniazid and rifampin). A patient 
is diagnosed with multidrug-resistant TB (MDR TB) if the tubercle bacilli are resistant to at least 
isoniazid and rifampin, the two best first-line TB treatment drugs. A patient is diagnosed with 
extensively drug-resistant TB (XDR TB) if the tubercle bacilli are resistant to isoniazid and rifampin, 
plus resistant to any fluoroquinolone and at least one of three injectable anti-TB drugs (such as 
amikacin, kanamycin, or capreomycin).
The results of drug susceptibility tests can help clinicians choose the appropriate drugs for treating each 
patient. This is very important. Patients with TB disease who are treated with drugs to which their strain of 
TB is resistant may not be cured. In fact, their strain of TB may become resistant to additional drugs.
The results of drug susceptibility tests can help clinicians  
choose the appropriate drugs for each patient.
Drug susceptibility tests should be repeated if a patient has a positive culture for M. tuberculosis after  
3 months of treatment or if a patient does not seem to be getting better. That way, the clinician can find 
out whether the patient’s strain of TB has become resistant to certain drugs; if necessary, the clinician may 
change the drugs used for treating the patient. Clinicians treating patients with drug-resistant TB should 
always consult with a medical expert who is familiar with the treatment of drug-resistant TB.
Drug susceptibility tests should be repeated if a patient has a  
positive culture for M. tuberculosis after 3 months of treatment  
or if a patient does not seem to be getting better.
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Growth-Based Drug Susceptibility Testing
Growth-based drug susceptibility testing can be done using a liquid medium or a solid medium method.  
In a drug susceptibility test, organisms that grow in media containing a specific drug are considered 
resistant to that drug (Figure 3.12). Liquid medium methods are faster than solid media methods for 
determining susceptibility to first-line TB medications (Figure 3.13). Usually the susceptibility results can be 
obtained within 7 to 14 days with the liquid medium method. Traditional solid medium methods can take 
as long as 21 days.
Molecular Detection of Drug Resistance
Drug resistance is due to the presence of mutations in specific M. tuberculosis genes. There are a variety of 
tests that can detect mutations associated with drug resistance. The tests are done on patient specimens 
or isolates from patient specimens. If a mutation thought to be associated with resistance is detected, the 
bacteria are considered to be drug resistant. Molecular tests can provide results within 24 to 48 hours. 
A limitation of molecular testing for drug resistance is that the clinical relevance of some mutations  
remains unknown. Further, not all biological mechanisms of resistance are known. As a result, if no 
mutations are detected by the molecular test, drug resistance cannot be ruled out. Therefore, it is  
essential that conventional growth-based drug susceptibility tests are done and used in conjunction 
with molecular results.
Molecular tests provide preliminary guidance on effective therapy for TB patients. Molecular detection of 
drug resistance should be considered for patients with the following characteristics:
zz High risk of rifampin resistance, including MDR TB (e.g., previously treated for TB, contact to 
someone with MDR TB, or non-U.S.–born from a high-risk country);
zz First-line drug susceptibility results are available and show resistance to rifampin;
zz Infectiousness poses a risk to vulnerable contacts (e.g., infants); and
zz Contraindications to essential first-line medications (e.g., rifampin allergy).
Module 3 – Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease58
Figure 3.12 Drug susceptibility testing on solid media. Organisms are 
resistant to the drug in the upper right compartment and susceptible 
to the drugs in the lower compartments. Upper left contains no drugs.
Figure 3.13 Drug susceptibility testing in liquid media.
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Study Questions 3.32–3.35
3.32 Why is it necessary to culture a specimen? Select one.
A. To determine how long the person has had TB disease
B. To determine whether the specimen contains M. tuberculosis
C. To determine whether the person will recover from TB disease
3.33  What does a positive culture for M. tuberculosis mean? How is this 
important for the TB diagnosis?
3.34 Why are drug susceptibility tests done? Choose the correct 
answer(s).
A. To determine which drugs will kill the tubercle bacilli that are causing disease 
in a particular patient
B. To see whether the patient is allergic to the drugs
C. To help clinicians choose appropriate drugs for each patient
D. To determine which drugs the patient is receiving
3.35 How often should drug susceptibility tests be done?
Answers to study questions are on pages 64–72
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Case Study 3.8
In the public health clinic, you see a patient, Ms. Sanchez, who 
complains of weight loss, fever, and a cough of 4 weeks duration. 
When questioned, she reports that she has been treated for TB 
disease in the past and that she occasionally injects heroin.
z What parts of Ms. Sanchez’s medical history lead you to suspect  
TB disease?
z What diagnostic tests should be done?
Answers to case study questions are on pages 73-77
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3
MODULE
TB Genotyping 
TB genotyping is a laboratory-based method that can determine the genetic pattern of the strain of  
M. tuberculosis that caused TB disease in a person. Each strain has a distinct genetic pattern, or genotype. 
Genotyping is done for culture-positive cases of TB disease. TB programs should work with laboratories 
to ensure that TB genotyping results are obtained for all culture-positive cases.
Genotyping has applications at both the population level and the individual patient level. At the 
population level, genotyping is most commonly used for detecting, refuting, and monitoring TB 
outbreaks. For more information about the use of genotyping in TB outbreaks, refer to Module 9, 
Tuberculosis Outbreak Detection and Response.
At the patient level, TB genotyping has three uses: 
zz Distinguishing relapse from reinfection
zz Detecting false-positive culture results
zz Informing contact investigations
Distinguishing Relapse from Reinfection
Some patients previously treated for TB disease may develop TB disease again. This could be due to a 
relapse or reinfection. Genotyping results can be used to distinguish relapse from reinfection. 
Recurrence of TB disease after treatment is most often due to relapse of TB disease. Relapse can occur 
for several reasons including inadequate treatment, nonadherence to treatment, or unidentified drug 
resistance. If genotype information from the first episode of TB is available, it can be compared with 
genotype information from the second episode. If the genotypes match, it is likely the TB disease was 
not completely cured the first time it was treated.
If the genotypes from the two episodes of TB disease do not match, it is likely the second episode 
occurred because the person became infected with a different strain of M. tuberculosis (reinfection).
Detecting False-Positive Cultures
Genotype information can alert laboratory and public health staff to situations where specimens from 
different patients, processed within the same facility and time period, share genotypes. When this 
situation occurs, the laboratory can follow a process to determine if an error has been made, and one or 
more of the cultures are falsely positive. False-positive TB cultures can be caused by cross-contamination 
of a specimen in the laboratory, clerical error such as mislabeling of specimens, or contaminated 
equipment such as a bronchoscope used to collect the samples. 
Identifying false-positive cultures is important because doing so helps prevent unnecessary treatment 
and contact investigations for persons who would otherwise be misdiagnosed with TB disease. 
Informing Contact Investigations
Typically, genotype information will not be available during the early stages of a contact investigation; 
however, when it is available, genotype results can help confirm, disprove, or detect connections among 
patients. For more information about the use of genotyping in contact investigations, refer to Module 8, 
Contact Investigations for Tuberculosis.
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3
MODULE
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Answers to Study Questions
3.1 What are the steps for conducting an IGRA?
To conduct an IGRA, health care workers should first read the instructions from 
the manufacturer and then follow the steps below:
zz Confirm arrangements for testing in a qualified laboratory.
zz Arrange for delivery of the blood sample to the laboratory in the time the 
laboratory specifies to ensure testing of samples with viable blood cells.
zz Draw a blood sample from the patient according to the test 
manufacturer’s instructions.
zz Schedule a follow-up appointment for the patient to receive test results.
zz Based on test results, provide follow-up evaluation and treatment  
as needed.
3.2 How are IGRA results interpreted? 
QFT-Plus results are based on the amount of IFN-γ that is released in response 
to the M. tuberculosis antigens and control substances. T-Spot results are based 
on the number of IFN-γ producing cells (spots) produced. Both the standard 
qualitative test interpretation (positive, negative, invalid, or indeterminate) and 
the quantitative assay measurements should be reported.
3.3 How should a negative IGRA result be interpreted?
If the result is negative, then the patient is unlikely to have M. tuberculosis 
infection and may not require further evaluation unless they have signs and 
symptoms of TB disease. Moreover, persons who have a negative test result can 
still have LTBI.
3.4 What are four advantages for using IGRAs as compared to the TST?
zz Requires single patient visit to conduct the test
zz Results can be available within 24 hours
zz Repeat IGRAs do not cause the booster phenomenon, which can happen 
with repeat TSTs
zz BCG vaccination does not affect IGRA results
3.5 What is the TST used for?  
The TST is used to determine whether a person has TB infection.
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Answers to Study Questions (Continued)
3.6 How is the TST given? 
The TST is given by using a needle and syringe to inject 0.1 ml of 5 tuberculin 
units of liquid tuberculin between the layers of the skin (intradermally), usually 
on the forearm.
3.7 With the TST, when is the patient’s arm examined? Select one.  
A. Immediately after the tuberculin is injected
B. 2 to 3 hours after the tuberculin is injected
C. 12 to 24 hours after the tuberculin is injected
D. 48 to 72 hours after the tuberculin is injected
The correct answer is D. The patient’s arm is examined 48 to 72 hours after the 
tuberculin is injected.
3.8 How is the induration measured? 
The diameter of the indurated area is measured across the forearm; erythema 
(redness) around the indurated area is not measured, because the presence of 
erythema does not indicate that a person has TB infection.
3.9 What two factors determine the interpretation of a TST reaction as 
positive or negative? What additional factor is considered for people 
who may be exposed to TB on the job?  
The two factors that are used to determine the interpretation of a TST include 
the size of the induration and the person’s risk factors for TB.
For people who may be exposed to TB on the job, an additional factor that is 
considered is the risk of exposure to TB in the person’s job.
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Answers to Study Questions (Continued)
3.10 Five or more millimeters of induration is considered a positive reaction 
for which of the following group(s)? Select the correct answer(s).
A. People living with HIV
B. Recent contacts of people with infectious TB
C. Mycobacteriology workers 
D. People with chest x-ray findings suggestive of previous TB disease
The correct answers are A, B, and D. An induration of 5 or more millimeters is 
considered a positive reaction for people living with HIV, recent contacts of people 
with infectious TB, and people with chest x-ray findings suggestive of previous TB 
disease. Five or more millimeters is also considered a positive reaction for people with 
organ transplants and other immunosuppressed patients (for example, patients on 
prolonged therapy with corticosteroids equivalent to/greater than 15 mg per day of 
prednisone or those taking TNF-alpha antagonists).
3.11 Ten or more millimeters of induration is considered a positive reaction 
for which of the following group(s)? Select the correct answer(s).  
A. Children younger than 5 years of age
B. People who abuse drugs
C. People who live or work in high-risk congregate settings
D. People with organ transplants
The correct answers are A, B, and C. An induration of 10 or more millimeters is 
considered a positive reaction for children younger than 5 years of age, people who 
abuse drugs, and people who live or work in high-risk congregate settings. Ten or 
more millimeters is also considered a positive reaction for people born in countries 
where TB disease is common, people who abuse drugs, mycobacteriology laboratory 
workers, people with certain medical conditions that place them at high risk for TB (for 
example, silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and 
certain intestinal conditions), and infants, children, or adolescents exposed to adults in 
high-risk categories.
3.12 For which group of people is 15 or more millimeters of induration 
considered a positive reaction? 
An induration of 15 or more millimeters is considered a positive reaction for people 
with no known risk factors for TB. 
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3.13 Name four factors that may cause false-positive reactions to the TST.  
zz Infection with nontuberculous mycobacteria (NTM) (mycobacteria other  
than M. tuberculosis)
zz Recent BCG vaccination
zz Administration of incorrect antigen (e.g., tetanus toxoid)
zz Incorrect measuring or interpretation of the TST reaction
3.14 Is there a reliable way to distinguish a positive TST reaction caused by 
vaccination with BCG from a reaction caused by true TB infection?  
No, there is no reliable way to distinguish a positive TST reaction caused by 
vaccination with BCG from a reaction caused by true TB infection. When using the  
TST, people with a positive reaction who have been vaccinated with BCG should 
always be further evaluated for LTBI or TB disease the same as if they were not 
vaccinated with BCG. 
3.15 Name six factors that can cause false-negative reactions to the TST. 
False-negative reactions may be due to
zz Anergy
zz Recent TB infection (within the past 8 to 10 weeks)
zz Very young age (younger than 6 months of age)
zz Recent live-virus measles or smallpox vaccination 
zz Incorrect method of giving the TST 
zz Incorrect measuring or interpretation of TST reaction
3.16 What is anergy?  
Anergy is the inability to react to skin tests because of a weakened immune system. 
Many conditions, such as HIV infection, cancer, or severe TB disease itself, may weaken 
the immune system and cause anergy. HIV infection is an important cause of anergy.
Answers to Study Questions (Continued)
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3.17 After TB germs have been transmitted to someone, how long does it take 
before TB infection can be detected by the TST? Select one. 
A. 3 to 5 days
B. 1 week
C. 2 to 8 weeks
D. 12 to 14 weeks
The correct answer is C. After TB has been transmitted, it takes 2 to 8 weeks before  
TB infection can be detected by the TST.
3.18 What should be done if a patient has a negative TST reaction but has 
symptoms of TB disease?  
Any patient with symptoms of TB disease should be evaluated for TB disease, regardless 
of his or her skin test reaction. In fact, people with symptoms of TB disease should be 
evaluated for TB disease right away, at the same time that the TST is given. 
3.19 What is the booster phenomenon?  
The booster phenomenon is a phenomenon in which people (especially older adults) 
who are skin tested many years after becoming infected with M. tuberculosis may have a 
negative reaction to an initial skin test, followed by a positive reaction to a skin test given 
up to a year later. This happens because in some people who have TB infection, the 
ability to react to tuberculin lessens over time. The first skin test “jogs the memory” of the 
immune system, boosting its ability to react to tuberculin.
3.20 What is the purpose of two-step testing? 
The purpose of two-step testing is to tell the difference between boosted reactions 
and reactions caused by recent infection. Because it provides accurate information 
about each employee’s baseline skin test reaction, two-step testing is used in many TB 
screening programs for skin testing employees when they start their job.
3.21 In what situation is two-step testing used? Select one. 
A. When testing people who have HIV/AIDS
B. When testing new employees in a TB testing program
C. When testing people who have diabetes 
D. When any patient’s first TST reaction is positive 
The correct answer is B. Two-step testing is used in many TB testing programs for skin 
testing employees when they start their job. 
Answers to Study Questions (Continued)
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3.22 How is two-step testing done?  
If a person has a negative reaction to an initial skin test, he or she is given a second test  
1 to 3 weeks later.
zz If the reaction to the second test is positive, it is considered a boosted reaction 
(due to TB infection that occurred a long time ago).
zz If the reaction to the second test is negative, the person is considered uninfected. 
In this person, a positive reaction to a TST given later on will probably be due to 
recent TB infection.
3.23 What are the five components for conducting a complete medical evaluation 
for diagnosing TB disease?  
zz Medical history
zz Physical examination
zz Test for TB infection
zz Chest x-ray
zz Bacteriologic examinations
3.24 What parts of a patient’s medical history should lead a clinician to suspect 
the possibility of TB?  
Clinicians should suspect the possibility of TB disease in patients who have
zz Symptoms of TB disease
zz Been exposed to a person who has infectious TB or has other risk factors for 
exposure to TB
zz Risk factors for developing TB disease
zz Had TB infection or TB disease before 
Answers to Study Questions (Continued)
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Answers to Study Questions (Continued)
3.25 Which of the following are symptoms of  TB disease? Select the 
correct answer(s). 
A. Fever
B. Weight loss
C. Runny nose
D. Cough lasting 3 or more weeks
The correct answers are A, B, and D. Fever, weight loss, and a cough lasting 3 
or more weeks are all symptoms of TB disease. Other symptoms of TB disease 
include fatigue, malaise, night sweats, pain in the chest when breathing or 
coughing, and coughing up sputum or blood.
The symptoms of extrapulmonary TB disease depend on the part of the body 
that is affected by the disease. For example, TB of the spine may cause pain in 
the back; TB of the kidney may cause blood in the urine. 
3.26 For patients with symptoms of TB disease, should clinicians wait 
for TST or IGRA results before starting other diagnostic tests?  
No. For patients with symptoms of TB disease, clinicians should not wait for TST 
or IGRA results before starting other diagnostic tests.
3.27 Name two purposes of the chest x-ray. 
The purposes of the chest x-ray are to 
zz Help rule out the possibility of pulmonary TB disease in a person who 
has a positive TST or IGRA result and no symptoms of TB
zz Check for lung abnormalities in people who have symptoms of TB 
disease
3.28 Can the results of a chest x-ray confirm that a person has TB 
disease? Why or why not?  
No, the results of a chest x-ray cannot confirm that a person has TB disease. 
This is because a variety of illnesses may produce abnormalities whose 
appearance on a chest x-ray resembles TB. Although an abnormality on a 
chest x-ray may lead a clinician to suspect TB, only a bacteriologic culture that 
is positive for M. tuberculosis confirms that a patient has TB disease. 
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3.29 What are the four ways to collect sputum specimens? Indicate which 
procedure is the least expensive and easiest to perform.  
zz Usually, patients who are suspected of having pulmonary TB disease 
simply cough up sputum and the sputum is collected in a sterile 
container for processing and examination. This is the least expensive and 
easiest procedure. If a patient cannot cough up sputum on his or her 
own, other techniques can be used to obtain a specimen.
zz An induced sputum sample can be obtained by having the patient inhale 
a saline (salt water) mist, which causes the patient to cough deeply. 
zz Bronchoscopy can be used to obtain pulmonary secretions or lung tissue. 
In this procedure, an instrument called the bronchoscope is passed 
through the nose or mouth directly into the diseased portion of the lung, 
and some sputum or lung tissue is removed. 
zz Gastric washing involves inserting a tube through the patient’s nose 
and passing it into the stomach. The idea is to get a sample of gastric 
secretions that contain sputum that has been coughed into the throat 
and then swallowed. 
3.30 What do laboratory personnel look for in a smear? Select one.
A. Acid-fast bacilli
B. White blood cells
C. Fast-moving bacilli
D. Drug-resistant bacilli
The correct answer is A. Laboratory personnel use the microscope to look for 
acid-fast bacilli (AFB) on the smear. AFB are mycobacteria that stay stained  
even after they have been washed in an acid solution. Tubercle bacilli are one 
kind of AFB.
3.31 What does a positive smear indicate about a patient’s 
infectiousness?  
The results of the smear examination can be used to help determine the 
infectiousness of the patient. Patients who have many tubercle bacilli in their 
sputum have a positive smear. Patients who have positive smears are considered 
infectious because they can cough many tubercle bacilli into the air. 
Answers to Study Questions (Continued)
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Answers to Study Questions (Continued)
3.32 Why is it necessary to culture a specimen? Select one.
A. To determine how long the person has had TB disease
B. To determine whether the specimen contains M. tuberculosis
C. To determine whether the person will recover from TB disease
The correct answer is B. Culturing the specimen is necessary to determine 
whether the specimen contains M. tuberculosis and to confirm a diagnosis of TB 
disease. (However, in some cases, patients are diagnosed with TB disease on the 
basis of their signs and symptoms, even if their specimen does not contain  
M. tuberculosis.) Additionally, culture is necessary for genotyping and for 
performing drug susceptibility testing. 
3.33 What does a positive culture for M. tuberculosis mean? How is this 
important for the TB diagnosis?  
A positive culture for M. tuberculosis means that M. tuberculosis has been identified 
in a patient’s culture. A positive culture for M. tuberculosis confirms the diagnosis 
of TB disease. 
3.34 Why are drug susceptibility tests done? Select the correct answer(s). 
A. To determine which drugs will kill the tubercle bacilli that are causing 
disease in a particular patient
B. To see whether the patient is allergic to the drugs
C. To help clinicians choose appropriate drugs for each patient 
D. To determine which drugs the patient is receiving
The correct answers are A and C. Drug susceptibility tests are done to determine 
which drugs will kill the tubercle bacilli that are causing disease in a particular 
patient. The results of drug susceptibility tests can help clinicians choose the 
appropriate drugs for each patient. 
3.35 How often should drug susceptibility tests be done?  
Drug susceptibility tests should be done when a patient is first found to have a 
positive culture for M. tuberculosis. In addition, drug susceptibility tests should be 
repeated if a patient has a positive culture for M. tuberculosis after 3 months of 
treatment or if a patient does not seem to be getting better.
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Case Study Answers
3.1   Which of the following patients have a positive TST reaction?
A. Mr. West, 36 years old, HIV infected, 8 mm of induration
B. Ms. Hernandez, 26 years old, native of Mexico, 7 mm of induration
C. Ms. Jones, 56 years old, has diabetes, 12 mm of induration
D. Mr. Sung, 79 years old, resident of a nursing home, 11 mm of 
induration
E. Mr. Williams, 21 years old, no known risk factors, 13 mm of induration
F. Ms. Marcos, 42 years old, chest x-ray findings suggestive of previous 
TB, 6 mm of induration
G. Ms. Rayle, 50 years old, husband has pulmonary TB, 9 mm of 
induration
A, C, D, F, and G all have positive TST reactions.  
3.2 A 30-year-old man who recently immigrated to the United States 
from India is given a TST and found to have 14 millimeters of 
induration. He reports that he was vaccinated with BCG as a child. 
He also says that his wife was treated for pulmonary TB disease  
last year.
z How should this man’s results be interpreted?
This man has a positive reaction to the TST (10 or more millimeters is 
considered a positive reaction for a person from a country where TB is 
common). Also, he is a contact of person with pulmonary TB (his wife). 
Because he was vaccinated with BCG there is a possibility that this may 
be a false-positive reaction. However, since there is no reliable way to 
distinguish a positive TST reaction caused by BCG or from a true TB 
infection, this man should be further evaluated for LTBI or TB disease as 
if he was never vaccinated with BCG.
z What factors make it more likely that this man’s positive 
reaction is due to TB infection?
This man is from an area of the world where TB is common, so he 
was probably exposed to TB in his native country. Therefore, he is at 
increased risk for TB infection. Also, his wife had pulmonary TB, which 
further increases the probability that he has been exposed to TB. 
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3.3 Mr. Bell comes to the TB clinic for a TST. He believes that he has 
been exposed to TB, and he knows he is at high risk for TB because 
he is HIV-infected. He is given a TST, and his reaction is read 48 
hours later as 0 millimeters of induration.
z What are three ways to interpret this result?
There are three possible reasons why Mr. Bell had no reaction to the 
tuberculin skin test. 
z First, he may not have TB infection. 
z Second, he may be anergic. People who are HIV-infected are more 
likely to be anergic than persons who are not HIV-infected. If Mr. Bell 
is anergic, he would be unable to react to tuberculin even if he did 
have TB infection. 
z Third, it may be less than 8 to 10 weeks since he was exposed to 
TB. After TB has been transmitted, it takes 2 to 8 weeks before TB 
infection can be detected by the TST. Mr. Bell should be retested 8 
to 10 weeks after he was last exposed to TB.
Case Study Answers (Continued)
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3.4 Ms. Wilson is a 60-year-old nurse. When she started a job at the local 
hospital, she was given a TST, her first test in 25 years. Her reaction 
was read 48 hours later as 0 millimeters of induration. Six months 
later, she was retested as part of the TB screening program in the 
unit where she works. Her TST reaction was read 48 hours later as  
11 millimeters of induration.
z What are two ways to interpret this result?
There are two possible explanations for this result. 
z One explanation is that Ms. Wilson may have been exposed to and 
infected with M. tuberculosis sometime in the 6 months between her 
first and second skin tests.
z The other explanation is the booster phenomenon. If Ms. Wilson was 
infected with M. tuberculosis many years ago, her ability to react to 
tuberculin may have decreased. This would explain why she did not 
react to the first TST. Then the first tuberculin test may have boosted 
the ability of her immune system to react to tuberculin. This would 
explain why she had a positive reaction to the second TST, which was 
given within a year of the first test. If this scenario is true, Ms. Wilson’s 
positive reaction would not mean that she was recently infected 
with M. tuberculosis. 
This problem in interpreting Ms. Wilson’s reaction would have been 
avoided if she had been tested with a two-step procedure when 
she first joined the hospital. In any event, because she has a positive 
reaction, Ms. Wilson should be evaluated for TB disease.
Case Study Answers (Continued)
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3.5 Mr. Lee has a cough and other symptoms of TB disease, and he is 
evaluated with a chest x-ray. However, he is unable to cough up any 
sputum on his own for the bacteriologic examination. 
z What should be done?
If a patient cannot cough up a sputum specimen, other techniques can be 
used to obtain sputum. First, clinicians can try to obtain an induced sputum 
sample. If they cannot obtain an induced sputum sample, a bronchoscopy  
or gastric washing may be done. 
3.6 Ms. Thompson gave three sputum specimens, which were sent to the 
laboratory for smear examination and culture. The smear results were 
reported as 4+, 3+, and 4+. 
z What do these results tell you about Ms. Thompson’s diagnosis  
and her infectiousness?
These results show that Ms. Thompson’s sputum specimens contain many 
acid-fast bacilli. Because the smears are positive, clinicians should suspect 
that Ms. Thompson has TB disease. They should also consider her infectious. 
However, it is possible that these acid-fast bacilli are mycobacteria other than 
tubercle bacilli. Therefore, the diagnosis of TB disease cannot be proven until 
the culture results are available.
3.7 Mr. Sagoo has symptoms of TB disease and a cavity on his chest x-ray, 
but all of his sputum smears are negative for acid-fast bacilli. 
z Does this rule out the diagnosis of pulmonary TB disease? 
No. 
z Why or why not?
M. tuberculosis may grow in the cultures even though there were no acid-
fast bacilli on the smear. Mr. Sagoo’s symptoms and his abnormal chest x-ray 
suggest that he does have pulmonary TB disease. 
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3.8 In the public health clinic, you see a patient, Ms. Sanchez, who 
complains of weight loss, fever, and a cough of 4 weeks’ duration. 
When questioned, she reports that she has been treated for TB 
disease in the past and that she occasionally injects heroin.
z What parts of Ms. Sanchez’s medical history lead you to 
suspect TB disease?
Ms. Sanchez has symptoms of TB disease (weight loss, fever, and a 
persistent cough). Also, in the past she has been treated for TB disease. 
We don’t know whether she completed therapy, but until we can 
prove otherwise, we should assume that she has TB disease again. Her 
history of injecting illegal drugs (heroin) is another risk factor for TB.
z What diagnostic tests should be done? 
People who have TB symptoms should be evaluated for TB disease. 
Because she has symptoms of pulmonary TB disease (coughing),  
Ms. Sanchez should be given a chest x-ray. In addition, a sputum 
specimen should be collected for smear and culture, blood for an HIV 
test, and drug susceptibility testing should be done if the culture is 
positive for M. tuberculosis.
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